Ahmed Maraey, Hadeer Elsharnoby, Mona Mahmoud, Paul Chacko, George V Moukarbel
{"title":"经皮左心耳闭塞术对缺血性脑卒中严重程度的影响。","authors":"Ahmed Maraey, Hadeer Elsharnoby, Mona Mahmoud, Paul Chacko, George V Moukarbel","doi":"10.1016/j.carrev.2024.12.007","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Percutaneous left atrial appendage occlusion (pLAAO) presents an alternative to anticoagulation (AC) for stroke prophylaxis in atrial fibrillation (Afib) patients with high bleeding risk. pLAAO was associated with lower rates of disabling stroke which was mainly attributed to the reduction of hemorrhagic stroke (HS). Little is known about the impact of pLAAO on the severity of ischemic strokes which we sought to study.</p><p><strong>Methods: </strong>The study is a retrospective analysis of the National Readmission Database for the years 2016-2020. All 6-month readmissions with IS after pLAAO admissions were identified. The control group comprised patients with Afib on AC who were admitted for IS. Patients with intracranial hemorrhage or those who underwent surgical LAAO were excluded. A propensity score matching system was utilized to match both groups. Treatment effects were presented as percentages and odds ratio (OR) with 95 % confidence interval (CI).</p><p><strong>Results: </strong>A total of 342 observations in each group were matched (weighted estimate: 583 in the pLAAO group and 663 in the control group). pLAAO group was associated with a decreased risk of fatal stroke (5.1 % vs. 10.0 %, OR: 0.48, 95 % CI [0.26-0.88], P = 0.018), and a decreased risk of non-fatal severe stroke (50.5 % vs. 59.6 %, OR: 0.69, 95 % CI [0.50-0.96], P = 0.029) at 6 months follow-up.</p><p><strong>Conclusion: </strong>Compared with patients on AC, patients with pLAAO admitted with ischemic strokes are less likely to have severe and fatal stroke. Further studies are needed to validate our findings.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of percutaneous left atrial appendage occlusion on the severity of ischemic stroke.\",\"authors\":\"Ahmed Maraey, Hadeer Elsharnoby, Mona Mahmoud, Paul Chacko, George V Moukarbel\",\"doi\":\"10.1016/j.carrev.2024.12.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Percutaneous left atrial appendage occlusion (pLAAO) presents an alternative to anticoagulation (AC) for stroke prophylaxis in atrial fibrillation (Afib) patients with high bleeding risk. pLAAO was associated with lower rates of disabling stroke which was mainly attributed to the reduction of hemorrhagic stroke (HS). Little is known about the impact of pLAAO on the severity of ischemic strokes which we sought to study.</p><p><strong>Methods: </strong>The study is a retrospective analysis of the National Readmission Database for the years 2016-2020. All 6-month readmissions with IS after pLAAO admissions were identified. The control group comprised patients with Afib on AC who were admitted for IS. Patients with intracranial hemorrhage or those who underwent surgical LAAO were excluded. A propensity score matching system was utilized to match both groups. Treatment effects were presented as percentages and odds ratio (OR) with 95 % confidence interval (CI).</p><p><strong>Results: </strong>A total of 342 observations in each group were matched (weighted estimate: 583 in the pLAAO group and 663 in the control group). pLAAO group was associated with a decreased risk of fatal stroke (5.1 % vs. 10.0 %, OR: 0.48, 95 % CI [0.26-0.88], P = 0.018), and a decreased risk of non-fatal severe stroke (50.5 % vs. 59.6 %, OR: 0.69, 95 % CI [0.50-0.96], P = 0.029) at 6 months follow-up.</p><p><strong>Conclusion: </strong>Compared with patients on AC, patients with pLAAO admitted with ischemic strokes are less likely to have severe and fatal stroke. Further studies are needed to validate our findings.</p>\",\"PeriodicalId\":47657,\"journal\":{\"name\":\"Cardiovascular Revascularization Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-12-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Revascularization Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.carrev.2024.12.007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2024.12.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景:经皮左心耳闭塞术(pLAAO)为高危房颤(Afib)患者提供了一种替代抗凝(AC)预防卒中的方法。pLAAO与较低的致残性中风发生率相关,这主要归因于出血性中风(HS)的减少。我们对pLAAO对缺血性中风严重程度的影响知之甚少。方法:本研究对2016-2020年美国国家再入院数据库进行回顾性分析。所有在pLAAO入学后6个月再入院的IS患者均被确定。对照组包括因IS入院的AC上房颤患者。排除颅内出血或行手术LAAO的患者。采用倾向评分匹配系统对两组进行匹配。治疗效果以百分比和比值比(OR)表示,置信区间为95%。结果:两组共匹配342条观察值(加权估计:pLAAO组583条,对照组663条)。pLAAO组与6个月随访时致死性卒中风险降低相关(5.1%比10.0%,OR: 0.48, 95% CI [0.26-0.88], P = 0.018),非致死性重度卒中风险降低相关(50.5%比59.6%,OR: 0.69, 95% CI [0.50-0.96], P = 0.029)。结论:与接受AC治疗的患者相比,pLAAO合并缺血性脑卒中患者发生严重致死性脑卒中的可能性较低。需要进一步的研究来验证我们的发现。
Impact of percutaneous left atrial appendage occlusion on the severity of ischemic stroke.
Background: Percutaneous left atrial appendage occlusion (pLAAO) presents an alternative to anticoagulation (AC) for stroke prophylaxis in atrial fibrillation (Afib) patients with high bleeding risk. pLAAO was associated with lower rates of disabling stroke which was mainly attributed to the reduction of hemorrhagic stroke (HS). Little is known about the impact of pLAAO on the severity of ischemic strokes which we sought to study.
Methods: The study is a retrospective analysis of the National Readmission Database for the years 2016-2020. All 6-month readmissions with IS after pLAAO admissions were identified. The control group comprised patients with Afib on AC who were admitted for IS. Patients with intracranial hemorrhage or those who underwent surgical LAAO were excluded. A propensity score matching system was utilized to match both groups. Treatment effects were presented as percentages and odds ratio (OR) with 95 % confidence interval (CI).
Results: A total of 342 observations in each group were matched (weighted estimate: 583 in the pLAAO group and 663 in the control group). pLAAO group was associated with a decreased risk of fatal stroke (5.1 % vs. 10.0 %, OR: 0.48, 95 % CI [0.26-0.88], P = 0.018), and a decreased risk of non-fatal severe stroke (50.5 % vs. 59.6 %, OR: 0.69, 95 % CI [0.50-0.96], P = 0.029) at 6 months follow-up.
Conclusion: Compared with patients on AC, patients with pLAAO admitted with ischemic strokes are less likely to have severe and fatal stroke. Further studies are needed to validate our findings.
期刊介绍:
Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.